Anti-angiogenic efficacy of aflibercept and bevacizumab in primary oral squamous cell carcinoma cells
| Autor: | Roshanak Monshizadeh, Neda Sadat Gohari, Sedigheh Rahrotaban, Meysam Ganjibakhsh, Parvaneh Farzaneh, Ata Gharajei, Ahmad Nasimian, Fereshteh Baghaei, Pouyan Aminishakib, Sahar Tavakoli Shiraji |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug Adult Male Vascular Endothelial Growth Factor A Cancer Research Bevacizumab Cell Survival media_common.quotation_subject Recombinant Fusion Proteins Angiogenesis Inhibitors Iran Pathology and Forensic Medicine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cell Movement Carcinoma Medicine Humans Secretion Aflibercept media_common Aged Cell Proliferation Aged 80 and over business.industry Cell growth Cell migration Middle Aged medicine.disease Vascular endothelial growth factor 030104 developmental biology Receptors Vascular Endothelial Growth Factor Otorhinolaryngology chemistry 030220 oncology & carcinogenesis Cancer research Carcinoma Squamous Cell Periodontics Female Mouth Neoplasms Oral Surgery business medicine.drug |
| Zdroj: | Journal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 47(6) |
| ISSN: | 1600-0714 |
| Popis: | Background In recent decades, anti-angiogenic treatment strategy has been well described in cancer treatment. The anti-angiogenic activity of both bevacizumab and aflibercept has been researched on 10 previously established primary oral squamous cell carcinoma (OSCC) cells of an Iranian population with different levels of purity, in an attempt to find the most effective anti-angiogenic-targeted drug. Methods To investigate and compare the effect of bevacizumab and aflibercept on vascular endothelial growth factor (VEGF) secretion of 10 primary OSCC cells, cell proliferation and viability were assessed by ELISA and MTT assays. In addition, cell migration was studied using scratch assay. Results The results showed that VEGF impressively expressed in all primary cancer cells. Although both drugs significantly reduced the secretion of VEGF, the effect of aflibercept was more prominent. Also, bevacizumab-treated cells migration was lower than the control group and the cells treated with aflibercept showed the lowest migration rate compared to bevacizumab and control groups. Conclusion The anti-angiogenic-targeted drugs, especially Af, might be effective in treatment of patients with OSCC in combination with conventional surgical treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text